Barbara Wezenter
Endocrinology, Diabetes & Metabolism · Bronx, NYNPI 1437374543
Payments from drug & device makers
Across 156 payments — averaging $22.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$424
- Xeris Pharmaceuticals, Inc.$296
- Amneal Pharmaceuticals LLC$280
- Amgen$272
- Lilly USA, LLC$266
- Radius Health, Inc.$245
- plus $2K from 23 others
What the payments were for
- Food & beverage$3,505100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 22 | $424 |
| Xeris Pharmaceuticals, Inc. | 19 | $296 |
| Amneal Pharmaceuticals LLC | 13 | $280 |
| Amgen | 8 | $272 |
| Lilly USA, LLC | 12 | $266 |
| Radius Health, Inc. | 10 | $245 |
| Dexcom, Inc. | 5 | $233 |
| AstraZeneca(2 entities) | 8 | $166 |
| Novo Nordisk | 9 | $166 |
| Sanofi-aventis U.S. LLC | 8 | $153 |
| Pfizer | 6 | $147 |
| Vifor Pharma, Inc. | 6 | $123 |
| Corcept Therapeutics | 4 | $122 |
| Mannkind Corporation | 3 | $93 |
| Insulet Corporation | 3 | $89 |
| Chiesi USA, Inc. | 3 | $67 |
| Johnson & Johnson | 2 | $57 |
| Zealand Pharma US, Inc. | 2 | $51 |
| Recordati_rare_diseases_inc. | 2 | $46 |
| Ferring Pharmaceuticals Inc. | 2 | $38 |
| Esperion Therapeutics, Inc. | 1 | $29 |
| Janssen Scientific Affairs, LLC | 1 | $22 |
| Ipsen Biopharmaceuticals, Inc | 1 | $22 |
| Medtronic | 1 | $19 |
| Ascendis Pharma Endocrinology Inc | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $18 |
| Tandem Diabetes Care, Inc. | 1 | $15 |
| Merck | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DEXCOM G6 TRANSMITTER$125
- EVENITY$125
How this compares
$3,505 in reported general payments places this provider in the 65th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
See all endocrinology, diabetes & metabolism providers in New York →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 50 | $99,232 |
| JardianceEmpagliflozin | 54 | $61,358 |
| ProliaDenosumab | 26 | $42,561 |
| FarxigaDapagliflozin Propanediol | 37 | $42,454 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 33 | $39,439 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 44 | $22,879 |
| JanuviaSitagliptin Phosphate | 11 | $13,805 |
| TrulicityDulaglutide | 12 | $10,974 |
| Novolog FlexpenInsulin Aspart | 37 | $9,700 |
| TradjentaLinagliptin | 12 | $5,896 |
| Ultra-Fine Mini Pen NeedlePen Needle, Diabetic | 39 | $3,877 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $1,783 |
| Levothyroxine Sodium | 62 | $1,162 |
| Repaglinide | 22 | $1,113 |
| Alcohol Prep PadsAlcohol Antiseptic Pads | 42 | $728 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $166 | $99,23250 claims |
| MerckJanumet Xr, Januvia | $14 | $53,24444 claims |
| AmgenProlia | $272 | $42,56126 claims |
| AstraZenecaFarxiga | $166 | $42,45437 claims |
| Lilly USA, LLCTrulicity | $266 | $10,97412 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $280 | $1,16262 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
Other endocrinology, diabetes & metabolism in Bronx
- Martin GrajowerBronx$713K
- Robert BuschAlbany$9.1M
- Anastasios ManessisNew York$4.4M
- Ruth WeinstockSyracuse$3.1M
- Adi CohenNew York$2.5M
- Ajay ChaudhuriBuffalo$2.4M
- Carol LevyNew York$2.2M
- Mishaela RubinNew York$2M
- Kenneth HershonNew Hyde Park$1.9M
- Michael ShanikSmithtown$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.